Paraplegia Prevention in Aortic Aneurysm Repair by Thoracoabdominal Staging

NCT03434314 — Not applicable, Unknown, 500 participants, University of Leipzig

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

Paraplegia Prevention in Aortic Aneurysm Repair by Thoracoabdominal Staging With 'Minimally-Invasive Segmental Artery Coil-Embolization': A Randomized Controlled Multicentre Trial - PAPAartis

RegistryNCT03434314, acronym PAPAartis
StatusUnknown
PhaseNot applicable
Study typeInterventional; randomized, parallel, masking: none, treatment
Enrollment500 (Estimated)
SponsorUniversity of Leipzig (Other); collaborators: European Commission, German Research Foundation, Universidad de Granada, European Clinical Research Infrastructure Network, Modus Research and Innovation Limited, Copenhagen University Hospital, Rigshospitalet, European Society of Cardiology, Baylor College of Medicine, University of Pennsylvania
ConditionsAortic Aneurysm, Thoracoabdominal
InterventionsMinimally-Invasive Segmental Artery Coil-Embolization (Procedure)
Datesstart 2018-11-08, primary completion 2025-06-01 (estimated), completion 2025-06-01 (estimated), first posted 2018-02-15, last updated 2024-04-11
Locations29 sites in Austria, France, Germany, Italy, Netherlands, Poland, Sweden, Switzerland and 1 more countries

Related Papers Related Patents Related Grants Related Experts
All trials for Aortic Aneurysm, Thoracoabdominal All trials of Minimally-Invasive Segmental Artery Coil-Embolization

-Summary

Aortic aneurysms represent the most common and dangerous aortic diseases. Although conventional aortic repair techniques cure the disease, there is a high risk of paraplegia particularly in extensive thoracoabdominal aneurysms due to impaired blood supply to the spinal cord.

The PAPA-ARTiS trial will assess the clinical safety and efficacy of the MISACE (Minimally-Invasive Segmental Artery Coil-Embolization) procedure, a novel therapeutic concept to reduce the risk of paraplegia due to aneurysm repair.

The study investigates the MISACE procedure as a potential pre-treatment prior to open or endovascular aneurysm repair in patients with thoracoabdominal aortic aneurysms. Patients will be randomized to one of the two treatment strategies: a) aneurysm repair without MISACE pre-treatment, or b) aneurysm repair with MISACE pre-treatment.

Expand all sections  ·  Collapse all

+Detailed description

Chronic aortic aneurysms are permanent and localized dilations of the aorta that remain asymptomatic for long periods of time, but continue to increase in diameter before they eventually rupture. Left untreated, the patients' prognosis is dismal, since the internal bleeding of the rupture brings about sudden death. Although successful treatment cures the disease, the risky procedures compromise spinal cord blood supply acutely and permanently, frequently leading to paraplegia, particularly for aneurysms involving crucial segmental arteries, i.e. thoracoabdominal aortic aneurysms of Crawford type II \& III. Although various strategies have achieved a remarkable decrease in the incidence of paraplegia, it is still no less than 10-20%.

However, it has recently been found that the deliberate staged occlusion of the segmental arteries to the paraspinous collateral network finally supplying the spinal cord can trigger arterial collateralization, thus stabilizing blood supply from alternate inflow sources and preventing ischaemia.

This has been translated to a clinically available therapeutic option, 'minimally invasive staged segmental artery coil embolization' (MISACE), which proceeds in a 'staged' manner to occlude groups of arteries under highly controlled conditions, after which time must be allowed for arteriogenesis to build a robust collateral blood supply.

PAPA-ARTiS is a multi-national, prospective, open-label, two-arm, randomized controlled trial to demonstrate, that a minimally invasive staged treatment approach can reduce paraplegia and mortality in patients undergoing thoracoabdominal aortic aneurysm (TAAA) repair.

Patients with planned aneurysm repair will be included in the study and will be randomized 1:1 in the control group or the MISACE-group. The control group receives treatment as per standard institutional protocol - open or endovascular repair without MISACE. In the MISACE-group, segmental arteries will be occluded in one to three sessions some weeks before the definite repair. Segmental arteries are occluded with coils or plugs.This induces arteriogenesis and the building of a robust collateral network ultimately supplying the spinal cord. During aneurysm repair, these new arteries provide an alternate blood supply to the spinal cord and thereby help prevent paraplegia.

+Arms and interventions

ArmTypeInterventionsDescription
MISACE armExperimentalProcedure: Minimally-Invasive Segmental Artery Coil-EmbolizationMinimally-Invasive Segmental Artery Coil-Embolization MISACE procedure prior to aneurysm repair segmental arteries are occluded with coils or plugs in one to three MISACE sessions (staged procedure)
control armNo interventionreceives treatment of aneurysm as usual: open surgical repair or endovascular repair without MISACE
  • Minimally-Invasive Segmental Artery Coil-Embolization (Procedure): During one single MISACE session 3-7 segmental arteries will be occluded. The procedure is conducted through a peripheral artery access in local anaesthesia. Microcoils or vascular plugs will be used for the occlusion itself.

+Outcome measures

Primary outcomes

  • The primary objective is to greatly reduce incidence of ischaemic spinal cord injury and mortality. [30 days after TAAA repair]: Successful treatment of the aneurysm is a binary variable. All of the following criteria must be met for this composite endpoint to count as a success: * The patient is alive and without substantial spinal cord injury 30 days after treatment, and * the aneurysm did not rupture and has been excluded within six months of randomization. Substantial spinal cord injury will be determined with a modified Tarlov scale (see below).

Secondary outcomes

  • substantial spinal cord injury [30 days after TAAA repair and at one year after TAAA repair]: Substantial spinal cord injury is defined as zero to two on the modified Tarlov scale. 0\. No lower extremity movement 1. Lower extremity motion without gravity 2. Lower extremity motion against gravity 3. Able to stand with assistance 4. Able to walk with assistance 5. Normal
  • spinal cord injury according to the modified Tarlov scale from TAAA repair to one year [from date of TAAA repair and up to one year after TAAA repair]: Spinal cord injury will be determined with a modified Tarlov scale (see above).
  • mortality [at 30 days and one year after TAAA repair]: all-cause mortality
  • stay in intensive care unit and intermediate care [from date of TAAA repair and up to one year after TAAA repair]: length of stay in intensive care unit and intermediate care unit after TAAA repair
  • sub-group analyses [up to one year after TAAA repair]: sub-group analyses of spinal cord injury according to modified Tarlov scale (see above) for open repair and endovascular repair separately
  • sub-group analyses [up to one year after TAAA repair]: sub-group analyses of mortality for open repair and endovascular repair separately
  • re-operation for bleeding [from date of TAAA repair and up to one year after TAAA repair]: re-operation for bleeding (only for open repair)
  • cross-clamping times [during open surgery]: cross-clamping times during open surgery
  • residual aneurysm sac perfusion [up to one year after TAAA repair]: residual aneurysm sac perfusion, i.e. type II endoleaks (only for endovascular repair)
  • costs [up to one year after TAAA repair]: incremental cost-effectiveness ratio (ICER) will be calculated
  • Quality Adjusted Life Years [up to one year after TAAA repair]: Quality Adjusted Life Years (QALYs) will be estimated over one year

+Eligibility

Sex: All, ages: 18 Years to any

Inclusion Criteria:

* TAAA, Crawford type II or III
* planned open or endovascular repair of aneurysm within four months
* ≥ 18 years old

Exclusion Criteria:

* complicated (sub-) acute type B aortic dissection
* ruptured and urgent aneurysm (emergencies)
* untreated aortic arch aneurysm
* bilaterally occluded iliac arteries or chronic total occlusion of left subclavian artery
* pre-operative neurological deficits or spinal cord dysfunction
* major untreated cardio-pulmonary disease
* life-expectancy of less than one year
* high risk for segmental artery embolism
* severe contrast agent allergy, severe reduction in glomerular filtration rate (CKD stage 4)
* expected lack of compliance
* pregnant or nursing women
* impaired thyroid function, if not under stable treatment
* women of child bearing potential without highly effective contraceptive measures
* current participation in other interventional clinical trial
* patients under legal supervision or guardianship
* patients placed in an institution by official or court order

+Locations (29)

FacilityCityCountryStatus
Medizinische Universität InnsbruckInnsbruckAustria
Herzzentrum HietzingViennaAustria
University Hospital of BordeauxBordeauxFrance
Marie Lannelongue HospitalLe Plessis-RobinsonFrance
Uniklinik RWTH AachenAachenGermany
Deutsches Herzzentrum BerlinBerlinGermany
Universitätsklinikum DüsseldorfDüsseldorfGermany
Westdeutsches Herz und Gefäßzentrum EssenEssenGermany
Universitäts-Herzzentrum Freiburg/ Bad KrozingenFreiburg im BreisgauGermany
Herzzentrum HamburgHamburgGermany
Medizinische Hochschule HannoverHanoverGermany
Universitätsklinikum HeidelbergHeidelbergGermany
Herzzentrum LeipzigLeipzigGermany
UniversitätskIinikum LeipzigLeipzigGermany
Klinikum rechts der Isar (TU München)MunichGermany
Klinikum der Universität München (LMU)MünchenGermany
Universitätsklinikum MünsterMünsterGermany
Paracelsus Universität - Klinikum NürnbergNurembergGermany
Universitätsklinikum RegensburgRegensburgGermany
Universitätsklinikum TübingenTübingenGermany
S.Orsola-Malpighi HospitalBolognaItaly
Ospedale San Raffaele SRLMilanItaly
Maastricht University Medical CenterMaastrichtNetherlands
Medical University of WarsawWarsawPoland
Silesian Center for Heart DiseasesZabrzePoland
Lund University Hospital MalmoeMalmöSweden
Örebro University HospitalÖrebroSweden
Bern University HospitalBernSwitzerland
St Bartholomews HospitalLondonUnited Kingdom

+Publications

  • Results publication: Petroff D, Czerny M, Kolbel T, Melissano G, Lonn L, Haunschild J, von Aspern K, Neuhaus P, Pelz J, Epstein DM, Romo-Aviles N, Piotrowski K, Etz CD. Paraplegia prevention in aortic aneurysm repair by thoracoabdominal staging with 'minimally invasive staged segmental artery coil embolisation' (MIS(2)ACE): trial protocol for a randomised controlled multicentre trial. BMJ Open. 2019 Mar 4;9(3):e025488. doi: 10.1136/bmjopen-2018-025488. PMID 30837256

+Investigators